The Effectiveness of Silodosin for Nocturnal Polyuria in Elderly Men With Benign Prostatic Hyperplasia: A Multicenter Study.
10.5213/inj.2015.19.3.190
- Author:
Young Won KIM
1
;
Jinsung PARK
;
Hong CHUNG
;
Hong Wook KIM
;
Hyung Joon KIM
;
Jae Hung JUNG
;
Won Tae KIM
Author Information
1. Department of Urology, Chungbuk National University College of Medicine, Cheongju, Korea. wtkimuro@chungbuk.ac.kr
- Publication Type:Multicenter Study ; Original Article
- Keywords:
Nocturia;
Adrenergic alpha-Antagonists;
Prostatic Hyperplasia
- MeSH:
Adrenergic alpha-Antagonists;
Aged*;
Humans;
Lost to Follow-Up;
Male;
Nocturia;
Patient Dropouts;
Polyuria*;
Prospective Studies;
Prostate;
Prostatic Hyperplasia*;
Quality of Life
- From:International Neurourology Journal
2015;19(3):190-196
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: To investigate improvement in nocturia and nocturnal polyuria in nocturnal polyuria patients after silodosin administration by using a 3-day frequency volume chart. METHODS: This was a prospective multicenter study. We enrolled nocturnal polyuria patients (nocturnal polyuria index [NPi]>0.33), aged > or =60 years, diagnosed with the 3-day frequency volume charts of patients with benign prostatic hyperplasia taking alpha-blockers. Of the 54 patients, 30 (55.6%) completed the study according to the study protocol (per-protocol group), and 24 dropped out (dropout group). RESULTS: Of the 24 patients in the dropout group, 5 withdrew consent due to side effects or lack of efficacy, 7 were lost to follow-up at 4 weeks, 8 were lost to follow-up at 12 weeks, and 4 dropped out due to failure to complete 3-day frequency volume charts at 12 weeks. In the per-protocol group, there was significant improvement in the International Prostate Symptom Score (IPSS), especially question numbers 1, 3, 4, 5, 6, 7, and the quality of life question (P=0.001, P=0.007, P<0.001, P=0.003, P=0.049, P<0.001, and P<0.001, respectively). The Leeds sleep evaluation questionnaire (LSEQ) score for the sleep question improved from 64.36 to 70.43 (P=0.039). The NPi reduced from 0.4005 to 0.3573 (P=0.027); however, in many cases, there was no improvement in nocturnal polyuria itself. In intention-to-treat analysis, there were significant improvements in IPSS and LSEQ in 45 patients. CONCLUSIONS: In elderly nocturnal polyuria patients, silodosin monotherapy exhibits good efficacy in improving nocturia and nocturnal polyuria; however, the mean NPi was still >0.33. Considering the high dropout rate of our study due to no implementation of 3-day frequency volume charts, prospective and large-scale studies are needed to confirm our results.
